Preface to Pachyonychia Congenita Symposium Proceedings  by Leachman, Sancy A. et al.
Preface to Pachyonychia Congenita Symposium Proceedings
Sancy A. Leachman, W. H. Irwin McLean,w Janice N. Schwartz,z and Mary E. Schwartzz
Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; wHuman Genetics Unit, Ninewells Hospital and Medical
School, University of Dundee, Dundee, UK; zPachyonychia Congenita Project (PC Project), Salt Lake City, Utah, USA
These Symposium Proceedings summarize current clinical,
therapeutic, and scientific challenges associated with de-
veloping effective treatments for pachyonychia congenita
(PC). The impetus for these papers was the First Interna-
tional Pachyonychia Congenita Symposium, held on Feb-
ruary 12–16, 2004, at the Yarrow Hotel in Park City, Utah.
This symposium was sponsored by The Pachyonychia
Congenita Fund (Pachyonychia Congenita Project/PC
Project), a USA public charity founded in November 2003,
which supports clinical and research activities related to the
treatment of pachyonychia congenita. The goal of this sym-
posium was to gather thought leaders, expert clinicians and
scientists to explore approaches to the treatment and even-
tual cure for the disorder. As reflected in these Symposium
Proceedings, the major topics of presentations included our
most current understanding of the clinical and histologic
features, therapeutic approaches, and the molecular ge-
netics of the disease. In addition, ‘‘special topics’’ sessions
focused on the most practical and efficient approaches to
developing an eventual cure for PC, including discussions
of the most useful model systems and genetic and phar-
macologic approaches. Finally, the difficulty of initiating
clinical trials and developing therapeutics for rare disorders
of the skin was discussed at considerable length, with an
emphasis on maximizing the relationship between acade-
mia and industry in this effort. All participants in this sym-
posium were encouraged to critically evaluate options, and
the roundtable discussion format permitted a productive
and frequently lively exchange of ideas and information.
Sancy Leachman, Patti Champine, Mary Schwartz, and
Jan Schwartz organized the symposium, which opened with
a series of lectures by Irwin McLean, Leonard Milstone,
Alfred Lewin, Markus Landthaler, Mario Capecchi, Olga
Igoucheva, and Roger Kaspar. These lectures focused on
potential gene therapy technologies that could be applied to
PC. The technologies that were considered included siRNA,
ribozymes, triplex oligonucleotides, homologous recombi-
nation techniques, RNA lassos, and other oligonucleotide-
mediated gene repair techniques. The RNA-mediated
technologies would aim to decrease the intracellular levels
of the affected keratin and would have the potential advan-
tages of being highly specific for the mutated RNA. These
techniques would also have a transient, and thus reversible,
character. The primary disadvantage to the RNA-based
approach is that it would likely require ongoing repetitive
administration in order to be effective. The gene correc-
tion therapies utilizing homologous recombination, triplex-
forming oligonucleotides, or other oligonucleotide-mediated
repair techniques have the advantage of offering a more
permanent correction of the mutated keratin, but are also
less feasible in the short-term because of the difficulty in
getting an adequate number of cells corrected in vivo. The
problem of delivering these types of gene therapy agents to
the nails and hyperkeratotic skin of PC patients was dis-
cussed in a lecture by Bhaskar Thyagarajan. It was con-
cluded by the conference attendees that delivery will be one
of the major obstacles to overcome in the treatment of PC.
The next session included a thorough examination of the
clinical, histologic, and molecular genetic features of PC
led by Philip Fleckman, Frances Smith, and Maurice van
Steensel. It has now become clear through mutation
screening of PC patients that the clinical phenotype of PC
is somewhat variable and that the two major categories,
PC-1 and PC-2, can be discriminated by mutations in K6a
or K16 for PC-1 and K6b or K17 for PC-2. The clinical and
genetic discussions ultimately led to the development of a
questionnaire designed to facilitate further elucidation of
genotype-phenotype relationships in PC. This questionnaire
has now been completed by 57 participants in the newly
formed PC Registry, and data from these questionnaires are
reported in Leachman et al in this issue.
The final session of the conference focused on the po-
tential model systems available to advance our understand-
ing of the pathogenesis of PC as well as serve as pre-
clinical models for therapeutic agents. Dennis Roop and
Pauline Wong described the currently available cellular and
mouse models. Consensus was reached by the group that a
PC mouse model would be an extremely valuable tool for
both basic and pre-clinical investigation. Various approach-
es to the development of this model were discussed, and it
was felt that one of the best strategies would be to create a
mutant K6a knock-in to try to replicate the dominant-neg-
ative effect of the mutation. It was also decided that models
containing only a minor modification of the mouse gene as
well as a ‘‘humanized’’ model containing human regulatory
regions should be attempted.
An important outcome of the meeting was the develop-
ment of the International Pachyonychia Congenita Consor-
tium (IPCC), a collaborative team of clinicians and scientists
interested in pursuing PC care and research. A major ac-
complishment of the IPCC has been the development of
a collaborative research strategy in which PC research
projects are integrated to maximize efficiency and minimize
cost by sharing key resources and reagents. The IPCC has
identified several important gaps in our understanding of PC
and in the approaches that have been taken toward devel-
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
1
oping treatments for the disorder. These major deficiencies
include the lack of good in vitro and in vivo model systems,
the lack of therapeutic agents, our inability to deliver ther-
apeutic agents to hyperkeratotic skin, and the lack of a
registry to organize PC patients and facilitate clinical trials.
Each of these deficiencies will need to be eliminated before
the goal of a treatment for PC may be realized.
In summary, the goal of these Symposium Proceedings is
to create a ‘‘PC Handbook’’ to summarize current knowl-
edge and discuss state-of-the-art options for therapeutics
in the future. Perhaps the most promising result of the IPCC
is the collaborative network that has developed and is
actively working to better understand PC to help these
patients. PC patients have commented online that, ‘‘Having
PC has taught me to count my blessings. My feet hurt, but I
do have feet. I enjoy sure knowledge that the people in my
life are solid individuals, who have demonstrated by their
actions that they are not superficial people who care about
looks or what others might say. It’s a big positive to know
my closest friends are not shallow, but terrific people with
strong character, who look at my heart and not at my
beautiful nails and feet.’’ It is our sincere hope that our
combined efforts will culminate in an improved lifestyle for
all PC patients.
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